UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of April 2022

 

Commission File Number: 001-39545

 

Orphazyme A/S in restructuring

(Translation of registrant’s name into English)

 

 

Ole Maaløes Vej 3, DK-2200

Copenhagen N

Denmark

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:  

☒ Form 20-F   ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

 

 

 

 

 

 

EXHIBIT LIST

 

Exhibit

 

Description

99.1

 

Company announcement dated April 7, 2022

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Orphazyme A/S in restructuring

 

 

 

 

Date: April 7, 2022

 

 

 

By:

 

/s/ Anders Vadsholt

 

 

 

 

 

 

Name

 

Anders Vadsholt

 

 

 

 

 

 

Title:

 

Chief Executive Officer

and Chief Financial Officer

 

 

 

Orphazyme AS (NASDAQ:ORPH)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024 Orphazyme AS 차트를 더 보려면 여기를 클릭.
Orphazyme AS (NASDAQ:ORPH)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024 Orphazyme AS 차트를 더 보려면 여기를 클릭.